Doctor explains: Hyperbaric Oxygen Therapy for Fatigue in Long COVID and ME/CFS – What Does the New Research Tell Us?

Hyperbaric Oxygen Therapy for Fatigue in Long COVID and ME/CFS – What Does the New Research Tell Us?
Could breathing oxygen under pressure help people with ME/CFS and Long COVID? Two recently published studies have renewed interest in hyperbaric oxygen therapy (HBOT), reporting improvements in fatigue, physical functioning, pain and aspects of cognitive performance.
The findings are interesting, particularly because one study specifically recruited people with ME/CFS rather than studying Long COVID alone. However, important limitations remain, and we need larger controlled trials before HBOT can be recommended as an established treatment.
In this article, I explain what the researchers found, how the treatment might work, and what it means for people living with ME/CFS and post-viral fatigue.
What is hyperbaric oxygen therapy?
Hyperbaric oxygen therapy involves breathing oxygen inside a specially designed chamber where the air pressure is increased above normal atmospheric pressure.
Under these conditions, more oxygen dissolves into the blood plasma, potentially increasing oxygen delivery to tissues.
HBOT is already used in certain established medical situations, including decompression sickness and selected difficult-to-heal wounds. However, its use for chronic fatigue conditions remains experimental.
Researchers have proposed several possible mechanisms through which HBOT might influence ME/CFS and Long COVID:
Mitochondrial function: potentially supporting cellular energy production.
Oxidative stress: influencing processes involved in cellular damage and inflammation.
Neuroinflammation: potentially modifying inflammatory activity affecting the brain and nervous system.
Cerebral circulation: potentially changing blood flow and oxygen availability within the brain.
Brain connectivity: influencing communication between different brain regions.
These mechanisms are biologically interesting, but it is important to distinguish proposed explanations from mechanisms actually demonstrated by clinical studies.
Study 1: Improvements in ME/CFS following 40 sessions of HBOT
The first study, published in the Journal of Translational Medicine in June 2026, is particularly relevant because it investigated people diagnosed with ME/CFS.
The research team, based at Charité University Hospital in Berlin, recruited 30 patients with ME/CFS and investigated the effects of 40 HBOT sessions.
Most participants (90%) had developed their illness following COVID-19, while the remaining participants had other infectious triggers.
Importantly, participants met the Canadian Consensus Criteria for ME/CFS, including post-exertional malaise (PEM).
What treatment did patients receive?
Participants received 40 sessions of HBOT over approximately 8–16 weeks.
Each session involved breathing 100% oxygen at twice normal atmospheric pressure (2 atmospheres absolute) for 90 minutes.
The researchers assessed several aspects of health, including:
Physical functioning and everyday activities.
Fatigue severity.
Pain.
Exercise capacity and muscle strength.
Cognitive performance.
Orthostatic intolerance.
Brain activity and connectivity using functional MRI.
What were the results?
The researchers reported several encouraging findings.
Physical functioning improved. The average physical functioning score on the SF-36 questionnaire increased by 6.3 points by the end of treatment. Four weeks after treatment, the improvement remained at 4.5 points compared with baseline.
Eleven of the 30 participants (37%) achieved an improvement of at least 10 points, which the researchers defined as a clinically meaningful response.
Fatigue improved. Participants showed a significant reduction in fatigue severity, measured using the Chalder Fatigue Scale.
Pain improved. Improvements were also observed in pain scores.
Cognitive performance improved. Tests showed improvements in information processing speed, alongside other measures of physical capacity and muscle strength.
Interestingly, functional MRI scans revealed changes in communication between the thalamus and other brain regions. The researchers observed that some abnormal connectivity patterns moved towards those seen in healthy controls following treatment.
The thalamus is an important brain structure involved in processing and distributing sensory information and regulating several aspects of brain function.
These findings raise interesting questions about the role of brain network regulation in ME/CFS.
Was the treatment tolerated?
Most participants completed the treatment, although some experienced difficulties.
Six patients discontinued early because of pressure-related discomfort in their ears or sinuses, or anxiety and tightness associated with treatment.
Temporary short-sightedness was reported in 17 participants, while 13 experienced ear pressure or mild pain. No major permanent complications were reported.
Importantly, the study excluded people who were too severely affected to travel regularly to the treatment centre.
This means that its findings cannot automatically be applied to people with severe or very severe ME/CFS.
Study 2: HBOT for Long COVID-related fatigue and brain fog
The second study, published in the Journal of Korean Medical Science in November 2026, investigated 49 people experiencing persistent fatigue following COVID-19.
Unlike the German study, this research specifically focused on Long COVID rather than requiring a formal ME/CFS diagnosis.
Participants received ten HBOT sessions, each lasting 90 minutes, at twice normal atmospheric pressure.
The researchers assessed fatigue, memory, attention, psychological symptoms and other persistent post-COVID symptoms.
What did the researchers find?
The results were striking.
Of the 49 participants who started treatment, 36 (73.5%) met the study's definition of recovery from fatigue following treatment.
Fatigue scores also decreased substantially.
Improvements were reported in several cognitive measures, particularly verbal memory and working memory. Anxiety, depression and sleep quality scores also improved.
The total number of reported post-COVID symptoms decreased following treatment.
However, there was an important safety consideration: seven participants (14.3%) discontinued treatment because of middle-ear barotrauma. These participants recovered without permanent complications.
The findings are encouraging, but the study design requires careful interpretation.
Does this mean HBOT works for ME/CFS?
This is where we need to be cautious.
Both studies reported improvements, but neither provides definitive proof that HBOT caused those improvements.
The German ME/CFS study was a prospective observational study involving only 30 patients. There was no untreated or sham-treatment comparison group.
Similarly, the Korean Long COVID study used a single-arm design without a control group.
Consequently, it is difficult to distinguish the specific effects of HBOT from other influences, including:
Natural fluctuations in symptoms.
Regression to the mean.
Placebo and expectation effects.
Changes in activity and lifestyle during treatment.
Other factors influencing recovery.
There were also differences between the two studies. The German study used 40 sessions and recruited people with formally diagnosed ME/CFS, whereas the Korean study used ten sessions in people with post-COVID fatigue.
We therefore cannot assume that the results are directly comparable or that ten sessions would be sufficient for ME/CFS.
Another important question concerns post-exertional malaise (PEM).
PEM is a defining feature of ME/CFS and involves a worsening of symptoms following physical, cognitive or emotional exertion, often with a delayed onset. Improvements in fatigue questionnaires do not necessarily demonstrate that PEM has resolved or that patients can safely increase their activity.
The German researchers adapted their treatment schedule to allow breaks between sessions. None of the 30 participants who completed treatment discontinued because of PEM or worsening of their other ME/CFS symptoms. However, the study was too small to establish safety across the full spectrum of ME/CFS severity.
What does this mean for patients?
These studies represent an interesting development in ME/CFS research.
For the first time, we have a relatively detailed prospective study investigating HBOT specifically in a group of patients meeting recognised ME/CFS diagnostic criteria, alongside a separate study reporting improvements in Long COVID-related fatigue and cognitive symptoms.
The findings also support further investigation into the relationship between cellular energy metabolism, oxidative stress, brain function and persistent post-viral symptoms.
However, HBOT should not currently be regarded as an established ME/CFS therapy. We need properly designed randomised, sham-controlled trials to determine whether the improvements are genuinely attributable to oxygen treatment, how long any benefits last, which patients might respond, and what treatment schedule is appropriate.
There are also practical considerations. HBOT requires repeated visits to specialist facilities, can cause ear pressure problems and temporary visual changes, and may be difficult for people with significant mobility limitations or severe PEM.
For people with ME/CFS, careful pacing and post-exertional malaise (PEM) management remain important. Treatment approaches should avoid provoking symptom deterioration, and patients should not feel pressured to increase physical activity simply because they are receiving a new therapy.
At present, there is no established evidence-based HBOT protocol that can be routinely recommended for ME/CFS.
My perspective as an ME/CFS specialist
I find these studies encouraging, particularly the German research, because it investigates people with ME/CFS rather than assuming that findings in Long COVID necessarily apply to everyone with chronic fatigue.
The changes in brain connectivity are also interesting. They provide another avenue for investigating how ME/CFS affects the functioning of the nervous system, rather than focusing exclusively on fatigue as an isolated symptom.
Nevertheless, promising observational findings are not the same as proven clinical effectiveness.
As a chronic fatigue syndrome specialist, I believe that the priority should be identifying treatments that produce meaningful and sustained improvements in patients' quality of life without triggering post-exertional deterioration.
Future research should establish whether HBOT can achieve this, which patients might benefit, and whether the effects persist over time.
For patients considering private ME/CFS clinic online assessments or treatment options, it is important to receive individualised advice rather than relying on promising early research alone.
The same principles apply to people seeking an online ME/CFS doctor, a Long COVID fatigue clinic, a post viral fatigue doctor or a fibromyalgia specialist online: treatment decisions should be based on the individual's diagnosis, symptoms, medical history and functional limitations.
The bottom line: Hyperbaric oxygen therapy is an interesting experimental approach for ME/CFS and Long COVID. The latest research provides reasons for further investigation, but it is too early to conclude that HBOT is an effective or established treatment.
References
Kim L, Cammà G, Peters CK, et al. (2026). Hyperbaric oxygen therapy improves clinical symptoms and functional capacity and modulates thalamic connectivity in ME/CFS: a prospective cohort study. Journal of Translational Medicine, 24, 744. https://doi.org/10.1186/s12967-026-08324-6
Lee Y, Chang JG, Lee K, Kim I, Lee SY. (2026). Efficacy and Safety of Hyperbaric Oxygen Therapy for Fatigue and Neurocognitive Symptoms in Long COVID: A Prospective Observational Study. Journal of Korean Medical Science, 41(43), e278. https://doi.org/10.3346/jkms.2026.41.e278
You can also explore the clinic's ME/CFS and related conditions information and read more about ME/CFS research, ME/CFS testing and ME/CFS therapy on the UK ME/CFS Specialist blog.
If you would like to discuss whether your symptoms fit ME/CFS, fibromyalgia, Long COVID or another post-viral condition, you can book an online specialist consultation or learn more about Prof. Dmitry Pshezhetskiy and his clinical and research work.
Prof. Dmitry Pshezhetskiy, MBBS, PhD, MRCGP
GMC 7494518 — Registered Medical Practitioner (GP)
Medical Disclaimer: The information provided in this article is for general educational and informational purposes only and does not constitute personalised medical advice, formal diagnosis, or treatment planning. Reading this content or communicating via this website does not establish a doctor-patient relationship with Prof Dmitry Pshezhetskiy. ME/CFS affects every individual differently; strategies discussed may not be suitable or safe for your specific health situation. Always consult your GP, specialist healthcare team, or NHS 111 regarding your personal medical concerns. In a medical emergency, please dial 999 or visit your nearest Emergency Department immediately. For a full disclaimer, see Medical Disclaimer & Terms of Use in Terms and Conditions on the policies page.
If you would like specialist assessment, learn more about our online consultations.





Comments